Skip to main content

Advertisement

Contact Nicolas Penel

From: Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

Contact corresponding author